SENSITITRE HEAMOPHILUS/STREPTOCOCCUS PNEUMONIAE (HP) MIC PLATE

K014259 · Trek Diagnostic Systems, Inc. · JWY · Mar 26, 2002 · Microbiology

Device Facts

Record IDK014259
Device NameSENSITITRE HEAMOPHILUS/STREPTOCOCCUS PNEUMONIAE (HP) MIC PLATE
ApplicantTrek Diagnostic Systems, Inc.
Product CodeJWY · Microbiology
Decision DateMar 26, 2002
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 866.1640
Device ClassClass 2

Intended Use

The Sensititre Haemophilus/Streptococcus pneumoniae (HP) MIC Susceptibility plate is an in vitro diagnostic product for clinical susceptibility testing of Streptococcus pneumoniae and Haemophilus influenzae. This 510(k) is for the removal of the statement in our package insert under Plate Reading and Interpretation of Results: "The panel may only be read manually." Replace this and interpretation of Results with: "The panel may be autoread or manually read when testing S. pneumoniae and manually read with Haemophilus." The Sensititre Haemophilus/Streptococcus pneumoniae MIC panel is for testing Streptococcus pneumoniae and Haemophilus influenzae isolates.

Device Story

Sensititre HP MIC Susceptibility Plates are in vitro diagnostic tools for determining antimicrobial susceptibility of S. pneumoniae and H. influenzae. Device allows for either manual or automated reading of S. pneumoniae plates, while H. influenzae plates remain restricted to manual reading. Clinical laboratory personnel use these plates to assess bacterial growth inhibition in the presence of various antimicrobial agents. Output consists of Minimum Inhibitory Concentration (MIC) values, which assist clinicians in selecting appropriate antibiotic therapies for patients. Device facilitates standardized susceptibility testing in clinical microbiology settings.

Clinical Evidence

Bench testing only. Validation performed to demonstrate that automated reading of S. pneumoniae MIC plates provides results equivalent to manual reading methods.

Technological Characteristics

Microtiter plate format containing dehydrated antimicrobial agents. Supports both manual visual inspection and automated optical reading systems for S. pneumoniae; manual reading only for H. influenzae.

Indications for Use

Indicated for in vitro clinical susceptibility testing of Streptococcus pneumoniae and Haemophilus influenzae isolates. Prescription use only.

Regulatory Classification

Identification

An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol featuring three abstract human profiles facing to the right, with flowing lines beneath them. ## MAR 2 6 2002 Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Ms. Cynthia C. Knapp Director of Lab Services Trek Diagnostic Systems, Inc. 29299 Clemens Road, Suite 1-K Westlake. OH 44145 k014259 Re: K014237 Trade/Device Name: Sensititre™ Haemophilus/Streptococcus pneumoniae (HP) MIC Susceptibility Plates Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial Susceptibility Test Powder Regulatory Class: Class II Product Code: JWY Dated: December 21, 2001 Received: December 26, 2001 Dear Ms. Knapp: We have reviewed your Section 510(k) premarket notification of intent to market the device we nave and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for use surved in the encreativent of the enactment date of the Medical Device Amendments, or to commerce prior to they 20, 1978, in occordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it 11 your de records of such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must corply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set Orth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {1}------------------------------------------------ Page 2 - This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed notification. The I Dri Intellig of succiantial vour device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 If you desire spociale arravitry four ovices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, (301) 594-4560. Additionally, for quice at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Illionmation on your responsionals and Consumer Assistance at its toll-free number (800) 638-2041 or Manufacturers International and Colless "http://www.fda.gov/cdrh/dsma/dsmamain.html". Sincerely yours, Steven Butman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ 510 (k) Number (If known): KO/4259 Device Name: Sensititre Haemophilus/Streptococcus pneumoniae (HP) MIC Susceptibility Plates. Indications For Use: The Sensititre Haemophilus/Streptococcus pneumoniae (HP) MIC Susceptibility plate is an in vitro diagnostic product for clinical susceptibility testing of Streptococcus pneumoniae and Haemophilus influenzae. This 510(k) is for the removal of the statement in our package insert under Plate Reading and Interpretation of Results: "The panel may only be read manually." Replace this and incelpretation of Rosel may be autoread or manually read when testing S. pneumoniae and manually read with Haemophilus." The Sensititre Haemophilus/Streptococcus pneumoniae MIC panel is for testing Streptococcus pneumoniae and Haemophilus influenzae isolates. ## (PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) | 12 | |-----------------------------------------------------------------------------------------------------| | <br>State of Million Company of the continues of the contributed<br>CONSULERS COLLECTION<br>------- | (Division Sian-Off) Division of Clinical Laboratory Devices 510(k) Number K014259 Prescription Use (Per 21 CFR 801.109 OR Over-The-Counter Use
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%